[The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia].
Tretiak. N N NN; Babenko. T F TF; Gaĭdukova. S N SN; Zverkova. A S AS; Beschastnaia. S P SP
Key Findings
- Combining thymalin with plasmapheresis accelerated clinical and hematological compensation in CLL patients compared to chemotherapy alone.
- The combined approach improved functional activity of the lymphoid (immune) system.
- The method was reported as the first attempt to use these specific immune‑modulating tools together in this disease.
Practical Outcomes
- For biohackers, the data suggest thymalin might have immune‑supporting effects, but the evidence is limited to a specific cancer patient group and involves plasmapheresis, a medical procedure not easily done at home. It does not provide a clear, safe protocol for general longevity or performance use, and more research is needed before considering it for everyday supplementation.
Summary
A study looked at adding the peptide thymalin and a procedure called plasmapheresis to the usual chemotherapy for people with chronic lymphoid leukemia. The combination seemed to help patients reach clinical and blood‑test improvements faster than chemotherapy alone, and it also appeared to boost the activity of the immune system.
Abstract
Results are submitted of study of the effectiveness of inclusion into the treatment program for patients with chronic lymphoid leukemia of specific (thymalin) and unspecific (plasmapheresis) means and modes of immune correction, which made for more rapid attaining clinical and hematological compensation by comparison with chemotherapeutic agents only. Furthermore, the method of combined use of drugs, attempted for the first time, permitted the functional activity of the lymphoid system to be improved, with the clinical and hematological compensation being achieved in a shorter space of time.
Study Information
pubmed
1998